Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc. -- KERX

        Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx
                       Biopharmaceuticals, Inc. -- KERX

PR Newswire

NEW YORK, Feb. 1, 2013

NEW YORK, Feb. 1, 2013 /PRNewswire/ --Notice is hereby given that Faruqi &
Faruqi, LLP has filed a class action lawsuit in the United States District
Court for the Southern District of New York, case no. 13 Civ. 0755, on behalf
of all persons who purchased Keryx Biopharmaceuticals, Inc. ("Keryx" or the
"Company") (NASDAQ CM: KERX) securities between June 1, 2009 and April 1, 2012
inclusive (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

If you wish to obtain information concerning this action or view a copy of the
complaint, you can do so by clicking here: www.faruqilaw.com/KERX

Keryx and its Chief Executive Officer Ron Bentsur are alleged to have violated
Section 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule
10b-5 promulgated thereunder. Specifically, the complaint alleges that
defendants mislead investors about the timing and success of Keryx's clinical
trial that tested whether the drug perifosine was effective in treating late
stage colorectal cancer.

On April 2, 2012, Keryx announced the top-line data from the perifosine X-PECT
Phase 3 Clinical Trial. The Company revealed that the trial for refractory
advanced colorectal cancer did not meet the primary endpoint of improving
overall patient survival versus capecitabine and a placebo. On this
disappointing news, Keryx share price plummeted from $4.98 on March 30, 2012
to $1.74 on April 2, 2012 – a decline of roughly 65%.

Plaintiff now seeks to recover damages on behalf of himself and all other
individual and institutional investors who bought Keryx securities between
June 1, 2009 and April 1, 2012, excluding defendants and their affiliates.
Plaintiff is represented by Faruqi & Faruqi, LLP, a law firm with extensive
experience in prosecuting class actions and actions involving corporate fraud.

If you purchased Keryx securities during the Class Period, you may, not later
than April 2, 2013, move the court to serve as lead plaintiff of the class, if
you so choose. In order to discuss this action, or if you have any questions
concerning this notice or your rights or interests, please contact

369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330

SOURCE Faruqi & Faruqi, LLP

Website: www.faruqilaw.com
Press spacebar to pause and continue. Press esc to stop.